About Genenta Science
Genenta Science is a company based in Milan (Italy) founded in 2014 by Pierluigi Paracchi. Genenta Science has raised $33.58 million across 4 funding rounds from investors including Mediobanca Private Banking, ENEA Tech e Biomedical and Qianzhan. The company has 13 employees as of December 31, 2024. Genenta Science offers products and services including Temferon™. Genenta Science operates in a competitive market with competitors including Spark Therapeutics, AskBio, Unity Biotechnology, Zymeworks and Generation Bio, among others.
- Headquarter Milan, Italy
- Employees 13 as on 31 Dec, 2024
- Founders Pierluigi Paracchi
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genenta Science Spa Sponsored Adr
-
Annual Revenue
Not available
-
Net Profit
-$9.64 M (USD)23.43as on Dec 31, 2024
-
EBITDA
-$10.51 M (USD)16.81as on Dec 31, 2024
-
Total Equity Funding
$33.58 M (USD)
in 4 rounds
-
Latest Funding Round
$21.9 M (USD), Post-IPO
Mar 19, 2025
-
Investors
Mediobanca Private Banking
& 2 more
-
Employee Count
13
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Genenta Science
Genenta Science is a publicly listed company on the NASDAQ with ticker symbol GNTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Genenta Science
Genenta Science offers a comprehensive portfolio of products and services, including Temferon™.
Delivers therapeutic payloads to tumor microenvironment for cancer treatment.
People of Genenta Science
Unlock access to complete
Funding Insights of Genenta Science
Genenta Science has successfully raised a total of $33.58M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.9 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genenta Science
Genenta Science has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mediobanca Private Banking, ENEA Tech e Biomedical and Qianzhan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Industry trends and market analysis are provided by Qianzhan.
|
Locked | Locked | Locked | |
|
Mediobanca Private Banking is focused on wealth management and investment banking.
|
Locked | Locked | Locked |
Investor details for Genenta Science
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genenta Science
Investment portfolio details for Genenta Science
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genenta Science
Detailed financials for Genenta Science
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genenta Science Comparisons
Peer comparison for Genenta Science
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genenta Science
Genenta Science operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spark Therapeutics, AskBio, Unity Biotechnology, Zymeworks and Generation Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Gene therapies for rare liver and eye diseases are developed.
|
|
| Locked | Locked | Locked |
Tumor-selective immunotherapies for cancer treatment are developed.
|
Detailed competitors of Genenta Science
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genenta Science
Complete news archive for Genenta Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genenta Science
Genenta Science was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Genenta Science is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Pierluigi Paracchi is the current CEO of Genenta Science. They have also founded this company.
Genenta Science is a funded company, having raised a total of $33.58M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Genenta Science is 13.
Genenta Science was founded in 2014 in Milan, Italy, with operations centered on biotechnology. Lentivirus-based gene and cell therapies are developed for cancer treatment, targeting solid tumors, hematological malignancies, and glioblastoma. The lead candidate, Temferon, is utilized as a hematopoietic stem progenitor cell immuno-gene therapy. Tie2-expressing monocytes are also employed in immunotherapies for various cancers. Focus is maintained on advancing these therapies through clinical development.
Genenta Science's top competitors include Spark Therapeutics, Generation Bio and AskBio.
Genenta Science offers Temferon™.
Yes, Genenta Science is publicly traded on NASDAQ under the ticker symbol GNTA.
Genenta Science has 3 investors. Key investors include Mediobanca Private Banking, ENEA Tech e Biomedical, and Qianzhan.
The ticker symbol of Genenta Science is GNTA on NASDAQ.